Treatment Outcomes in a Decentralized Antiretroviral Therapy Program: A Comparison of Two Levels of Care in North Central Nigeria

Table 4

Risk factors for death within 12 months and virologic failure in patients initiating ART in a decentralized HIV treatment program (2007–2011) in Jos, Nigeria.

Variable	Death			Virologic failure
	AHR	95% CI	𝑃 value	AHR	95% CI	𝑃 value
Sex
Female	1			1
Male	1.60	1.06–2.42	0.02	0.88	0.66–1.18	0.40
Age (years)
<35	1			1
35–49	1.66	1.07–2.56	0.02	1.22	0.66–2.26	0.52
≥50	1.21	0.63–2.30	0.55	1.11	0.52–2.35	0.77
Baseline CD4 (cells/mm^3)
≥200	1			1.30	1.00–1.69	0.04
51–199	0.87	0.56–1.34	0.53	1.50	0.34–6.54	0.58
≤50	2.3	1.42–3.70	0.0006	5.13	1.93–13.65	0.001
Program level
Prime site	1			1
Satellite sites	5.05	3.31–7.70	<0.001	0.98	0.77–1.26	0.92
Haemoglobin (g/dL)
≥8	1			1
<8	2.86	1.30–6.29	0.008	1.16	0.67–2.01	0.57
WHO stage
1 and 2	1			1
3 and 4	0.99	0.66–1.49	0.98	1.50	1.22–2.06	0.0005
Creatinine (μmol/L)
≤120	1			1
>120	1.09	0.59–2.01	0.77	1.05	0.63–1.76	0.83
Formal education
Any	1			1
None	0.85	0.51–1.43	0.57	0.85	0.60–1.20	0.36